

Index

A

Abbott: alumni association and, 214; autonomy and, 105; Baxter and, 18–19, 78–80, 94; biotech industry and, 15–17, 212–213; career imprint of, 143–145, 168–176, 255–258; competition with, 130; developmental readiness and, 90; educational background and, 98–99; FDA and, 78–80, 174; globalization and, 71; quality problem, 130–131; 22; Schuler and, 99; strategy of, 236; structure of, 242; Vincent and, 212, 219, 225–226, 241
ABIOMED, Inc., 45
Active reflection, 269–270
Adams, Dan, 224
Age, development and, 88–90, 92–93
Albertsons, 4, 266
Allen, Dick, 76
Allied-Signal, 5, 225–226
Alumni reunions, 211, 214, 285
American Can Company, 41
American Home Products, 21, 36
American Hospital Supply (AHS), 15, 22, 24, 45, 210
Amgen, 169, 224–225
Amherst College, 37
Amylin Pharmaceuticals, 39
Aquila Biopharmaceuticals, 41
Arthur, M. B., xxi, 332, 337, 346
Assistant-to positions, 63, 76, 104, 110, 346
AT&T, 273

B

Bae, S. C., 322
Bain & Company, 286, 353
Barley, S., 309, 331, 343, 346, 353
Bartlett, Christopher, 217
Baum, J.A.C., 319
Baxter, Don, 24
Baxter Boys, xi, xix, xxiv, 7, 19, 21, 37, 39, 45, 50, 94, 254, 270, 274, 288–289, 294
Baxter International: Abbott and, 18–19, 78–80, 94; biotech industry and, 3–4, 6, 45–50, 183, 212–213, 218; as breeding ground, 53–56; career imprint of, 145, 181–199, 255–259; Carpenter and, 39–41;

Chubb and, 41–43; comparisons to, 17–19, 94; dissatisfaction within, 200–205; ecosystem perspective, 209–211; educational background and, 98–101; external competition and, 77–80; FDA and, 41, 72, 80, 191–192; generalists at, 122; Genetics Institute and, 210, 214–215, 284; globalization and, 71; Greene and, 37–39; human resources at, 64; impact of, 14–17; IPOs and, 3, 89, 315–325; managers from, 3; organizational changes, 49, 200–201; organizational culture, 57; overhauling plants, 72–74; personality types at, 86; prior work experience and, 101–104; product highlights, 328–330; Schmergel and, 21–37; senior executives, 89; Termeer and, 43–45; typical career path, 110–113; venture capitalists and, 186–193, 201, 204. *See also* Entrepreneurial spawning

Bayer, 183

Behavior, role-modeling, 63–64, 208–209, 356.
See also Organizational socialization

Bennis, W. G., 10, 72, 80, 292, 309

Beyer, J. M., 261

BIO, 331

Biogen: background, 224–227; Genzyme vs., 221; organizational culture, 242–249; organizational strategy, 228–237; organizational structure, 237–242; Vincent and, 99, 169, 219–220

Biological imprinting, 9

Biomatrix, 223

Biotechnology industry: Baxter and, 3–4, 6, 14–17, 45–50, 182–183, 218; career imprinting and, 256–257; Carpenter and, 49, 146; Chubb and, 42, 47–49, 182; comparison of executives, 169; competition within, 17–18; gender of management, 59; Greene and, 40, 182, 271; IPO teams and, 15, 89, 144; management transition waves, 213; Schmergel and, 21, 34–36, 271; Termeer and, 44–45, 49–50, 182, 219, 271; Vincent and, 219.
See also specific companies

Blair, Henry, 220

Boje, D. M., 125–126

Booz Allen, 6

Bossidy, Larry, 5

- Boston Medical Investors, 41
 Boston Scientific, 208
 Bottom-line performance, 60, 123–124, 160
 Boundary spanning career imprint, 155, 168, 176
 Boundaryless careers, 332, 337
 Bowyer, J. W., 322
 Boyer, Herbert W., 47, 197, 355
 Brewer, M. B., 319
 Bridgewater, Dolph, 41
 Bristol-Myers Squibb, 15–17, 89, 98
 Brown Shoe Company, 42
 Burke, James, 66, 93, 156, 163, 165
 Burrill, G. S., 320
 Bushee, B. J., 317–318
 Byers, Brook, 189–190, 209
- C**
- Calabrese, T., 319
 California Institute of Technology, 38
 Camaraderie, 64, 130, 132
 Capabilities: career development and, 10; comparisons of, 177; defined, 9; managerial transitions and, 266; venture capitalists on, 192, 195; war references and, 131
 Capelli, P., 341
 Cardiac Science, 41
 Career anchor, 11, 280, 335
 Career development: Baxter and, 53–54; biotech transition waves, 212; business context and, 13; final polish, 110–111, 114, 124–125; fit and, 97–105; general management, 110–111, 114, 118–122; imprinting and, 9–11; patterns in, 125–139; project-based assignments, 110–111, 113–118, 170; readiness and, 86–97; rotation, 111, 114, 120–122, 170
 Career imprint/career imprinting: consequences of, 13–14; contingent value of, 282–290; defined, 9; dimensions of, 9–11; dynamics of, 278–282; generalizable consequences of, 290–293; on individuals, 256–271; overview, 4–8; process of, 12–13
 Career transitions: biotech industry waves, 212–213; capabilities and, 266; developmental readiness and, 91–97; peer networks and, 209; senior executives and, 8
 Carpenter, Bob: alumni reunions, 211; biotech and, 49, 146, 184; Chubb and, 41; engineering and, 101; final polish and, 112, 124; GMP and, 113; importance of connections, 152; Integrated Genetics, 223; peer networks and, 207–208; sense of urgency and, 60–61; story of, 39–41; stretch assignments, 72; Termeer and, 44
 Carter, R. B., 322–323
 Castaldi, Dave: on biological products, 203; ecosystem perspective, 210; engineering and, 100; Pchildius and, 117; on strategy, 69; Termeer and, 44
 CEOs: biotech transition waves, 212–213; mini, 123, 201, 262; turnover in, 6
- Cetus, 181, 224, 355
 Chaltiel, Victor, 76
 Charan, Ram, 5
 Charles River Laboratories, 43
 Chatman, J. A., xiii, 341–345
 Christensen, C., 287
 Christensen, Gustav, 115–116, 139, 182, 287
 Chubb, Steve: biotech and, 47–49, 182, 184; Carpenter and, 39; on developmental readiness, 88–89; final polish and, 112, 124; story of, 41–43; stretch assignments, 72
 Claman, P. H., 335
 Clark, Paul, 169, 212
 Clinical Assays, 80
 Coca-Cola, 103
 Cognition: career development and, 11; defined, 9–10; Graham and, 137; prior work experience and, 261; venture capitalists on, 192; war references and, 131
 Cohen, S. N., 47
 Collective identity, 57–58, 63, 66
 Collins, Art, 169
 Competition: Abbott and, 130; Baxter and, 64, 130; biotech industry and, 17–18; external, 77–80; Genentech and, 224; war references and, 131
 Confidence: assignments building, 139; Baxter and, 194–195; career development and, 10; comparisons in, 177; defined, 9–10; evaluation and, 75–76; Graham and, 137; J&J and, 166–167, 177; learning-based efficacy, 121; stretch opportunities and, 67; venture capitalists on, 192, 196
 Connections: Abbott and, 174, 177; Baxter and, 177, 191, 194–195, 210; business context and, 266; career development and, 10, 119–120; defined, 9–10; extraorganizational, 121–122, 265; Graham and, 137; impact of, 10; importance of, 152; intraorganizational, 132; J&J and, 165–166, 177; learning through, 195; Merck and, 153–155, 177; peer networks, 206–209; relationships and, 9; Termeer and, 152, 191; Tobin on, 195, 208; venture capitalists on, 192; war references and, 131
 Contract research organizations (CROs), 236
 Corporate strategy. *See* Organizational strategy
 Custodial view, 63
 Cytex, 38–39
 Cytogen, 42
- D**
- Darby, M. R., 319
 Darden Business School, 43
 Dark, F. H., 322
 Dearborn, D. C., 261
 DEC (Digital Equipment Corporation), xv, 5, 280, 291
 Deeds, D. L., 320
 DeFillippi, R. J., 335
 DeLong, T. J., xii, 336
 DiMaggio, P. J., 363

Demonstrated success, 55, 75–80
 Development. *See* Career development
 Developmental fit: educational background
 and, 98–101; evolution of, 104–105;
 opportunities and, 98; overview, 97;
 prior work experience, 101–104;
 values and, 101
 Developmental readiness: age and, 88–90;
 career stage and, 90–91; overview,
 86–88; transitions and, 91–97
 Don Baxter Intravenous Products, Inc., 24
 Douglas, Gordon, 152
 Douglas, Richard, 89, 243
 Dow Chemical, 22
 Dress, attention to, 58, 118
 Dreyer, Bill, 38
 Dutton, J., 344

E

Eccles, R. G., 126
 Ecosystem perspective, 209–211, 284
 Educational background, developmental fit
 and, 98–101
 Efficacy: 10, 75–76, 155, 166–167; learning-
 based, 114, 121, 127, 137, 140, 162, 166,
 266, 309, 355
 Egosyntonic, 346
 Eisenhardt, K. M., 295, 310
 Elan Corporation, 227
 Eli Lilly: age of senior executives, 89;
 educational background and, 98;
 growth of biotech industry and,
 15–17; Hybritech and, 39; products of, 197
 Engineering, educational background
 in, 100–101
 Entrepreneurial career imprint, xxi, xxvi, 6,
 140–143, 176, 181, 184–187, 198, 204,
 232, 239, 245, 259, 274, 280–288
 Entrepreneurial spawning: Baxter and, 14–15,
 17–19, 125, 159, 182–199, 259; biotech
 transition waves, 212–213; defined, 141,
 253; factors facilitating, 7, 200–215
 Enzon, 169
 Epimmune, 39
 Erck, Stan, 288
 European Medical Evaluation Agency
 (EMA), 227
 Evaluation, confidence and, 75–76
 External competition, demonstrated success
 and, 77–80

F

Factor VIII, 35
 Fairchild, 6–7, 290
 Falk, Ralph, 24–25
 Fast-track jobs, 89–90, 103
 FDA: Abbott and, 78–80, 174; Baxter and,
 41, 72, 80, 191–192; Biogen and, 226;
 Genzyme and, 244–245; good manufac-
 turing practices, 72–73
 Federal Reserve Bank, 268
 Fenwal Laboratories, 24–25, 40, 79, 151

Fernandez, R. M., 356
 Filial imprinting, 8, 333
 Fliers, Walter, 224
 Fortune 500 company, 32
 Fully integrated pharmaceutical company
 (FIPCO), 183, 239
 Functional career imprint, 168, 172,
 175–176, 236, 242, 259, 262, 273
 Fungibility, sense of, 60–62

G

Gabarro, J., 335, 341
 Gantz, Bill: on active reflection, 269–270;
 on biological products, 203; biotech and,
 182; Christensen and, 115–116; on
 coaching, 123; ecosystem perspective,
 210; on final polish, 124; military experi-
 ence, 102; Moufflet and, 138; Schmergel
 and, 29–30, 32–33; Termeer and, 83
 Gault, Stanley, 292
 GelTex Pharmaceuticals, Inc., 40
 Genentech: Baxter and, 34; Biogen and, 248;
 biotech industry and, 182; Boyer and, 48;
 Chubb and, 42; competition and, 224;
 founding of, 47, 197; products of, 198;
 Raab at, 169; Schmergel on, 22
 General Electric (GE): career transitions and,
 332; as entrepreneurial spawner, 17;
 Gault and, 292; headhunter mantra, 3, 5;
 Johnston and, 4; organizational structure
 of, 13; playbook, 265–266
 General Mills, 267–268
 Generalists, 122, 347
 Genetic engineering: background, 197;
 Baxter and, 47, 202; Greene and, 38;
 Schmergel and, 34–35
 Genetics Institute: Baxter and, 210,
 214–215, 284; peer networks, 208;
 products of, 198; Schmergel at, 21, 36,
 182, 197, 250–252
 Genzyme: background, 220–224; Biogen vs.,
 221; career imprints and, 279, 281, 283;
 Carpenter and, 41; Douglas and, 89; Inte-
 grated Genetics and, 40; organizational
 culture, 242–249; organizational strategy,
 228–237; organizational structure,
 237–242; products of, 197; RDLFs and,
 358; Termeer and, 44–45, 218–223, 251,
 284
 Gerster, Lou, 361
 Gilbert, Wally, 220, 224–225, 243
 Glaser, B. G., 295
 Glaxo, 191
 Glesne, C., 301
 Globalization, 71, 229
 Gompers, P. A., 15, 185, 320
 Good manufacturing practices (GMP),
 60–61, 301; FDA and, 72–73; project-
 based assignments, 113
 Gorman, M., 321
 Graham, William: alumni reunions and, 214;
 on Baxter way, 93; birthday celebration,

211; bottom-line performance and, 60; business challenges and, 74; career patterns and, 126–127, 132–137; as CEO, 25, 47; ecosystem perspective, 210; end of era, 34, 49; entrepreneurial imprint and, 282; FDA and, 80; Fenwal and, 79; Great Depression and, 58; Greene and, 37; innovations and, 47; J&J and, 18, 144; Loucks and, 33; merit-based promotion, 102; new hires and, 48–49, 62, 65, 91, 99, 124; observations on, 57; optimizing company, 122; organizational structure, 239; retirement of, 200–201; on rotations, 123; Schmergel and, 26, 27, 30, 32, 65, 71; strategy and, 69, 128–129, 136, 199, 231, 245; talent source, 286; Termeer and, 43; Wollaeger and, 61

Great Depression, 58–59

Greene, Ted: Baxter and, 354; on biological products, 203; biotech and, 34, 182, 184, 271; Carpenter and, 40; peer networks, 208; Schmergel and, 40; story of, 37–39; Termeer and, 44

Greylock, 34–35

Grove, Andy, 290

Groysberg, B., xii, 332

Gulati, R., xiii, 315, 353–354

Gunz, H., 361

H

Ha Ngoc, Tuan, 208

Hall, Douglas T., 347

Hambrecht & Quist Healthcare Investors, 45, 285

Hambrecht & Quist Life Sciences Investors, 45

Harvard Business School: Carpenter at, 39; Chaltiel at, 76; Greene at, 37; Loucks at, 34; Schmergel at, 22

Haveman, H. A., 362

Hayes, Bob, 120

Headhunters: Abbott alumni and, 214; on Baxter executives, 187, 196; Chubb and, 42; on GE executives, 3, 5; Greene and, 38; management talent and, 6; organizational imprints and, 262, 272

Heaphy, E. D., 344

Heckman, J. J., 316

Henderson, Phil, 43

Henderson, R., 353, 356, 362

Hewlett Packard, 6

Higgins, Arthur, 169

Higgins, Bob, 53, 193

Higgins, Monica C., xxi, 11, 280, 315, 335, 342, 344–346, 354, 356, 361

Hill, Linda, 118

Hillback, Elliott, 119–121, 125, 139, 182, 283

Hoechst, 183

Holodnak, Bill, 199, 285–286

Home Depot, 266

Homosocial reproduction, 342

Honeywell, 5

Horan, John, 148

Huberman, A. M., 310

Human capital, 9, 61

Human resources, 64, 120–121

Hybritech, 39, 182, 208

Hyland Diagnostics, 42, 110

Hyland Laboratories, 25

I

I-deals, 342

Ibarra, H., 270

IBM, 5, 17, 58, 273, 361

ICOS, 169

Identity, collective, 57–58, 63, 66

IG Laboratories, Inc., 40, 223

Imprinting: biological, 9; defined, 334; filial, 8, 333; organizational life and, 339. *See also* Career imprinting

Institutional capital, 331

Institutional isomorphism, 363

Institutional system of meaning, 92–97

Integrated Genetics, Inc., 40, 182, 223

Interpersonal system of meaning, 92–93

IPOs: Baxter and, 3, 89; Biogen and, 225; biotech industry and, 15, 89, 144, 259

J

Jennett, Bill, 37, 39–40

Johnson, Larry, 266

Johnson, Pitch, 190

Johnson & Johnson: autonomy and, 105; Baxter and, 18; biotech industry and, 15–17, 212–213; Burke at, 66, 93; career imprint of, 143–146, 155–168, 255–257, 259–261; educational background and, 98; financial success of, 78; globalization and, 71; high-commitment value of, 58; human resources at, 64; institutional system of meaning, 93–94

Johnston, Larry, 4

Jones, C., xiii, 362

Junior military officers (JMOs), 99–100

K

Kanter, R. M., 10, 75, 309, 347

Keeler, Willie, 343

Kegan, R. K., 92

Kenyon, Mike, 211

Khurana, R., xii, 332

Kidder Peabody, 230–231

Kimbell, John, 79, 131

Klein, D. P., 322

Kleiner, Eugene, 290

Kleiner, Perkins, Caufield, and Byers, 38

Knowles, Jeremy, 243

Kolff, Willem, 24

Kotter, John, 265, 347

Kram, K., xii, 335, 361

L

Lacey, Jerry, 115

Laughlin, P., 99

Lawrence, B. S., xii, 331, 346, 349
 Lawrence, P. R., xii, 345
 Learning: career imprinting and, 333; on the job, 115–118; sources of, 54; through connections, 195; through stretch opportunities, 75
 Learning-based efficacy, 114, 121, 127, 137, 140, 162, 166, 266, 309, 355
 Lee, K., 320
 Lerner, J., 15, 185, 319
 Liability of newness, 334
 Logics of action, 217, 262
 Lorsch, J. W., xii, 341, 345
Los Angeles Times, 267
 Loucks, Vern: alumni reunions and, 211; Carpenter and, 39; as CEO, 49; FDA and, 72; Graham and, 33; organizational design choices, 280; promotion, 40; Schmergel and, 28–29; Tobin and, 135

M

Management: Abbott and, 168–169, 258; Baxter career path and, 110–111, 258; biotech transition waves, 212–213; career imprinting on, 9–11, 256–271; general, 110–111, 114, 118–122; at J&J, 155–156; at Merck, 147; mobility and, 59; no-go decisions, 117; rotation through jobs in, 121–124; transition to, 118–121; venture capitalists on, 192; by walking around, 136. *See also* Senior executives
 Managers: from Baxter, 3; career imprints of, 6; demonstrated success and, 76; expectations of, 60; extraorganizational relationships and, 122–123; gender of, 59; international assignments, 71–72; mobility of, 59; prior work experience of, 261
 Manaster, S., 322
 March, J. G., 261, 334
 Massachusetts Institute of Technology (MIT), xxi–xxii, 42–43, 47, 149, 219
 Matritech, 43
 McKinsey, 31, 37, 41
 Medtronic, 99, 169
 Megginson, W. L., 320, 323
 Mentoring, 118
 Merck: assistant-to positions and, 63; Baxter and, 18; biotech industry and, 15–17, 212–213; career imprint of, 6, 143–144, 146–155, 255–257, 259; educational background and, 98, 101; financial success of, 78; globalization and, 71; high-commitment value of, 58; human resources at, 64; stretch assignments at, 74; Vagelos at, 66, 74, 104; values at, 103–104
 Merck, George, 148
 Merit-based promotion system, 102–103
 Miles, M. B., 310
 Military, recruitment from, 99–104
 Miller, Mark, 169

Mobility: management and, 59; organizational imprints and, 260; of senior executives, 15; tournament, 342
 Monsanto, 240
 Moufflet, Gerard, 138–139, 182
 Mount Auburn Hospital (Massachusetts), 43
 Mr. Graham, 25, 65, 72, 81, 121, 126–127, 132–137, 141, 166, 201, 210, 282, 308, 348
 Murray, Ken, 224, 226

N

Nardelli, Robert, 266
 National Institutes of Health (NIH), 220, 224
 New York Stock Exchange, 25
New York Times, 267
 Newness, liability of, 334
 Nobel Prize, 224, 226
 Noe, C. F., 318
 Nohria, N., 126, 332, 347, 357
 Northwestern University, 41
 Nothing is impossible, 96, 126–127, 137–139, 240

O

O'Connell, Des, 31
 Oddi, Ray, 91, 116
 Oil embargo, 69
 Opportunities: developmental fit and, 98; perceived, 193–196, 262. *See also* Stretch opportunities
 O'Reilly, C. A., 341–345, 362
 “Organization man,” 58, 80, 81
 Organizational culture: career imprinting process and, 12–13, 66; social reinforcement and, 55–62; Termeer/Vincent and, 242–249
 Organizational socialization, 12, 55, 62–66, 336
 Organizational strategy: as career imprint factor, 12–13; Graham and, 68, 128–129, 136, 199, 231, 245; scientific innovation as, 74; stretch opportunities and, 55, 68–70; Termeer/Vincent and, 227–237; Willie Keeler strategy, 68, 231, 266, 343
 Organizational structure: of Baxter, 70–75; of General Electric, 13; Stinchcombe on, 8–9; Termeer/Vincent and, 237–242

P

Paths: as career imprint factor, 12, 107–108, 264; of Schmergel, 108–110
 Peer networks, 206–209
 People: as career imprint factor, 12–13; developmental fit and, 97–105; developmental readiness and, 88–97
 Peptimmune, Inc., 41
 Performance: bottom-line, 60, 123–124, 160; lack of, 112; stretch opportunities and, 68

Perkins, Tom, 38
 Pfeffer, J., 342
 Pfizer, 152–153, 191
 Phildius, Pete, 41, 117, 211
 Piccolo, Lance, 195
 Pisano, G. P., 321
 Place: as career imprint factor, 12–13; demonstrated success, 75–80; developmental fit and, 104–105; social reinforcement and, 55–66; stretch opportunities, 66–75
 Planning, at Baxter, 138–139
 Plasma-Vac product, 24
 Podolny, J. M., 322
 Porter, M. E., 317–318
 Pour bottle, 78–79
 Powell, W. W., 331, 363
 Pragmatism, 138–139, 198
 Prior work experience: cognition and, 261; developmental fit and, 87, developmental readiness and, 91, 101–104; stretch opportunities and, 68
 Procter & Gamble, 103
 Profit and loss (P&L), 53–54, 98, 158, 175, 186, 189–191, 193, 199, 217–218, 232, 239, 241, 271
 Promotion system, merit-based, 102–103
 Prudential Securities, 230, 244

Q

Quality problems, Abbott and, 130–131, 174
 Quinn, R. E., 308, 344, 348–349

R

Raab, Kirk, 169
 Rao, H., 356, 360
 Rathmann, George, 169, 188, 212
 Recognition, demonstrated success and, 55, 75–77
 Recruiters. *See* Headhunters
 Regional advantage, 7–8, 184
 Relationships. *See* Connections
 Rensselaer Polytechnic Institute (RPI), 22
 Research and development limited partnerships (RDLPs), 358
 Research design and methods: data analysis, 307–313; focal interviews, 300–304; interviews, 304–305; overview, 295–296; participant observation, 305–307; qualitative data collection, 297–300; quantitative data collection, 296–297
 Rewards, demonstrated success and, 55, 75–77
 Roberts, L., xii, 344, 350
 Roche, 183, 225
 Role-modeling behavior, 63–64, 208–209, 356
 Rosa, Joe, 224, 228, 241, 243
 Rountree, Dekle, 39, 41
 Rousseau, D., xii, 332, 336–337, 341–342, 355, 362
 Rubbermaid, 292

S

Sahlman, W. A., 321
 Sandoz, 183
 Sato, Vicki, 235
 Saxenian, A., 291, 320
 Schafer, Ray, 224
 Scharfstein, D. S., 15, 185
 Schaubert, Steve, 39, 41, 113, 182
 Schein, E. H., xxix, 56, 300
 Schering, 183, 240
 Schering-Plough, 226
 Schmergel, Gabe: alumni reunions, 211; biotech and, 34–36, 184, 201, 271; career path of, 108–110; Castaldi on, 69; Christensen and, 116; on confidence, 195; confidence-building assignments, 139; developmental readiness and, 88; as general manager of Germany, 26–29, 71, 118–119; Genetics Institute and, 21, 36, 182, 197, 250–252; Graham and, 65; Greene and, 40; institutional balance and, 95; operations in Belgium, 29–30; on organizational culture, 57; overcoming obstacles, 121; peer networks and, 207; as president of International, 32–34; recruitment, 93; rotation in jobs, 122; senior management, 31, 49, 125, 159; starting at Baxter, 23–26; story of, 19, 22–36; Termeer and, 43–44, 83; on two strikes mentality, 124; VP of Europe, 32; worldview of, 103
 Schor, Leon, 208
 Schuler, Jack, 99, 169–170
 Schwartz, Charlie, 23, 26–27, 29–31
 Scientific career imprint, xxi, 6, 147, 155, 176, 259
 Scientific innovation, as business strategy, 74
 Scott, Doug, 54, 211
 Self-efficacy, 75–76
 Senior executives: age of, 89; career development and, 10; career imprints, 3–8, 268–269; mobility of, 15; selective attention and, 261; socialization and, 64–65; venture capitalists and, 18–19
 Sharp, Phillip, 224, 226, 243
 Sharpe and Dohme, 148
 Silverman, B. S., 319
 Simon, H. A., 261
 Simons, Bob, 162
 Singh, A. K., 322
 Smith, Dale, 40, 151
 SmithKline Beecham, 226
 Social capital, 9, 331
 Social reinforcement, 55–66, 270
 Socialization. *See* Organizational socialization
 Spawning. *See* Entrepreneurial spawning
 Spreitzer, G., 344
 Stanford Business School, 76, 99
 Stanford University, 47, 182
 Staples, 267
 Stericycle, 169
 Stinchcombe, A. L., 8–9, 333–334

Strategy. *See* Organizational strategy
 Strauss, A. L., 295
 Stretch opportunities: career imprinting and, 66–68; defined, 55; developmental fit and, 98; learning through, 75; organizational strategy and, 55, 68–70; organizational structure and, 70–75; overcoming obstacles, 121–122; taking initiative with, 138
 Stuart, T. E., 322
 Success: collective experience of, 205–206; demonstrated, 55, 75–80
 Sutter Hill, 40
 Swanson, Bob, 42, 197, 355
 Syntex, 38, 183
 Systems of meaning (Kegan), 92–97

T

T-Cell Sciences, 42
 Team, sense of, 59
 Technology, 5–6
 Termeer, Henri: on biological products, 203–204; biotech and, 44–45, 49–50, 182, 184, 271; career imprints and, 281; Castaldi on, 69; confidence-building assignments, 139; connections and, 152, 191; as general manager, 83; Genzyme and, 44–45, 218–223, 251, 284; organizational culture, 242–249; organizational strategy, 227–237; organizational structure, 237–242; overcoming obstacles, 121; passion of, 136; peer networks and, 208; story of, 43–45
 Texas Instruments (TI), 169–170, 219, 225, 241
 Thomas, D. A., xii, 335
 Thomas, R. J., 72, 309
Time, 48
 Times Mirror, 267–268
 Tobin, Jim: biotech and, 182; on connections, 195, 208; engineering and, 100; on Graham, 135; military experience, 102; on Schmergel, 21–22; Vincent and, 247
 Total Quality Management, 72
 Tournament mobility, 342
 Transactive memory systems, 351
 Transfuso-Vac product, 24, 328
 Transitions. *See* Career transitions
 Turnover, 201
 Tushman, M., xii, 287, 345, 362
 20/20, 77–78, 126–129, 131, 232
 Tylenol incident, 165–166, 351–352

U

University of California, 41, 182
 University of Virginia, 43
 University of Washington, 203
 Urgency, sense of, 60–61

V

VacTex, Inc., 41
 Vagelos, Ray, 66, 74, 103–104, 148–149
 Values, developmental fit and, 101
 Van de Ven, W., 316
 Van Maanen, J., 336, 338, 342, 346
 Van Praag, B., 316
 Venrock, 35
 Venture capitalists (VC): Baxter and, 49, 186–193, 201, 204; Biogen and, 224; Carpenter and, 40; consideration set of, 18–19, 195–196, 217–218; early biotech industry and, 184; Genzyme and, 220, 222; Johnson & Johnson and, 259; organizational imprints and, 262, 272; role of, 291; Schmergel and, 34–35; on top-notch managerial talent, 144; worldviews of, 185, 253
 VentureXpert, 321
 Vietnam, 102–103
 Vincent, Jim: Abbott and, 212; Biogen and, 99, 169, 219–220, 225–226; organizational culture, 242–249; organizational strategy, 227–237; organizational structure, 237–242; Texas Instruments and, 170
 VitaResc AG, 41

W

Wall Street Journal, 3, 266
 Walsh, J. P., 261
 Walter, Carl, 24
 War, 126–127, 129–132, 348
 Weinberg, N., 356
 Weiss, K. A., 320
 Weissmann, Charles, 224, 243
 Welch, Jack, 265
 White, Tony, 151
 Whitney, 35
 Whyte, W. H., 337, 341
 Willes, Mark, 267–268
 Willie Keeler strategy, 68, 231, 266, 343
 Wollaeger, Tim, 61, 70, 208
 Work experience, developmental fit and, 101–104
 World War II, impact of, 58–59
 Worldviews: career development and, 11; cognition and, 10; from Graham, 136; military experience and, 103; of venture capitalists, 185, 253
 WR Grace, 22

Z

Zucker, L. G., 319
 Zurlo, Gene, 211